focus -WSS

focus

author：fashion 2025-10-03 00:40:47 - browse：15

Novo Nordisk Denmark — LISELOTTE SABROE/AFP/Getty Images

An oral version of semaglutide, the drug marketed as Ozempic and Wegovy, led to dramatic weight loss in a trial enrolling people with obesity, manufacturer Novo Nordisk said Monday, data that could bolster what is already a blockbuster medicine.

In the study, which enrolled nearly 700 adults classified as having overweight or obesity, patients treated with a daily semaglutide tablet lost 15.1% of their body weight over the course of 17 months, while those on placebo lost 2.4%, Novo Nordisk said. The result is comparable to weekly injections of Wegovy, which in an earlier study led to 14.9% weight loss over the same period of time. In both studies, the most common side effects were gastrointestinal distress, with the majority of cases graded mild or moderate, the company said.

Novo Nordisk said it plans to submit oral semaglutide for U.S. and E.U. approvals later this year. A lower-dose version of the drug is already approved as a treatment for type 2 diabetes under the brand name Rybelsus.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： SNAP should offer more nutrition education

WSS

How to keep neuroscience’s past racism from being its future

Private equity deals in Medicare Advantage declines

Medicare Advantage proposed rates disappoint insurers

Why did Pfizer dish out millions for a Super Bowl ad?

Medical mystery: When a cough is not just a cough

To avoid data mishandling cases, universities eye AI and other tools

entertainment

focus

hotspot

Affirmative action in medical school literally saved lives

Medicare drug price negotiation hasn't dried up venture capital

Apple is now the first public company to be valued at $3 trillion

For Medicare Advantage, Democrats want stronger protections around AI

Medical records are filled with copy

SNAP should offer more nutrition education

How one medical school became remarkably diverse

Drinking less cuts risk of oral cavity, esophageal cancer: Report

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Medicare Advantage proposed rates disappoint insurers

hotspot

Why health records don't always know when patients are dead

What we’ve learned from the Aduhelm mess

The Readout: Gilead, Bernie Sanders, and other pharma news

Bristol Myers buys into radiopharmaceuticals with RayzeBio

Medical mystery: When a cough is not just a cough

Christmas in the PICU brings some surprising joy

leisure time

explore

knowledge

Wikipedia